| Companies sponsors |
AstraZeneca (durvalumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
AMMF – The Cholangiocarcinoma Charity |
| Professional groups |
Association of Cancer Physicians |
| |
British Association for the Study of the Liver |
| |
Cancer Research UK |
| |
Cholangiocarcinoma-UK |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| Associated public health groups |
None |
| Comparator companies |
Accord Healthcare (capecitabine, cisplatin, fluorouracil, gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Dr. Reddy's Laboratories (capecitabine) (confidentiality agreement not signed, not participating) |
| |
Glenmark Pharmaceuticals (capecitabine) (confidentiality agreement not signed, not participating) |
| |
Medac Pharma (fluorouracil, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Morningside Healthcare (capecitabine) (confidentiality agreement not signed, not participating) |
| |
Pfizer (cisplatin, fluorouracil, gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Sandoz (cisplatin) (confidentiality agreement not signed, not participating) |
| |
Seacross Pharmaceuticals (oxaliplatin) (confidentiality agreement not signed, not participating) |
| |
Sun Pharma (gemcitabine, oxaliplatin) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |